UMIN-CTR Clinical Trial

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000041915
Receipt No. R000044359
Scientific Title Identification of biomarkers that predict responsiveness to Dupilumab among severe asthma
Date of disclosure of the study information 2020/09/28
Last modified on 2022/06/01 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Identification of biomarkers that predict responsiveness to Dupilumab among severe asthma
Acronym Biomarker for Dupilumab
Scientific Title Identification of biomarkers that predict responsiveness to Dupilumab among severe asthma
Scientific Title:Acronym Biomarker for Dupilumab
Region
Japan

Condition
Condition asthma
Classification by specialty
Medicine in general Clinical immunology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Identification of biomarkers that predict responsiveness to Dupilumab
Basic objectives2 Others
Basic objectives -Others Clarify effectiveness of Dupilumab among severe asthma.
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Relationships between a change in GETE and serum cytokine levels
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Patient with severe asthma
2. Patient going to use Dupilumab
3. Patient using high dose ICS and other control agents
Key exclusion criteria Patient whom the researchers think is not suitable for the study.
Target sample size 15

Research contact person
Name of lead principal investigator
1st name Maho
Middle name
Last name Suzukawa
Organization National Hospital Organization Tokyo National Hospital
Division name Clinical Research Center
Zip code 204-8585
Address 3-1-1 Takeoka, Kiyose-Shi, Tokyo, Japan
TEL 042-491-2111
Email fueta-tky@umin.ac.jp

Public contact
Name of contact person
1st name Maho
Middle name
Last name Suzukawa
Organization National Hospital Organization Tokyo National Hospital
Division name Clinical Research Center
Zip code 204-8585
Address 3-1-1 Takeoka, Kiyose-Shi, Tokyo, Japan
TEL 042-491-2111
Homepage URL
Email fueta-tky@umin.ac.jp

Sponsor
Institute National Hospital Organization Tokyo National Hospital
Institute
Department

Funding Source
Organization National Hospital Organization Tokyo National Hospital
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Institutional Ethics Review Board of National Hospital Organization Tokyo National Hospital
Address 3-1-1 Takeoka, Kiyose-Shi, Tokyo, Japan
Tel 042-491-2111
Email tsukahara.rie.tz@mail.hosp.go.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 09 Month 28 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2019 Year 03 Month 22 Day
Date of IRB
2019 Year 04 Month 30 Day
Anticipated trial start date
2019 Year 05 Month 01 Day
Last follow-up date
2022 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information This study will end at March, 31, 2023.

Management information
Registered date
2020 Year 09 Month 28 Day
Last modified on
2022 Year 06 Month 01 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044359